NASDAQ$IVVD
Invivyd Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Invivyd reported Q1 2026 product revenue of $13.7M and a net loss of $41.4M.
For the three months ended March 31, 2026, Invivyd generated $13.7 million of net product revenue (+21% YoY) but reported a net loss of $41.4 million as R&D rose to $30.7 million from $10.6 million. SG&A was $25.1 million. The company commercializes PEMGARDA and other immunology assets while funding broader pipeline work.
- Product revenue $13.7M vs $11.3M prior-year quarter.
- Net loss $41.4M driven by stepped-up R&D investment.
- R&D $30.7M includes pipeline and Adimab-related activities.
- Other income $1.7M partially offset operating loss.
- Loss from operations $(43.1)M vs $(16.9)M a year ago.
Headline financials
Revenue & EPS history
Invivyd · Revenue · Quarterly
$13.7M
Forward guidance
Commercial-stage biotech without numeric annual guidance in the 10-Q; focus on PEMGARDA uptake and clinical spend.
Tailwinds
- Product revenue grew double digits year over year.
- Commercial infrastructure supports immunology portfolio.
Headwinds
- R&D ramp sharply increased quarterly loss.
- High SG&A for commercial and development functions.
- Competitive and reimbursement dynamics in infectious disease mAbs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2026
-1.7%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-16.8%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+18.4%
Q4 2021
Best reaction
-21.6%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -21.6% | -30.4% | -48.5% | |
| Q4 2025 | +2.4% | +7.0% | -25.1% | |
| Q3 2025 | +1.3% | +8.6% | +46.7% | |
| Q1 2025 | -15.8% | -3.2% | -5.3% | |
| Q4 2024 | +2.6% | -8.3% | -29.2% | |
| Q3 2024 | -15.2% | -13.8% | -38.5% | |
| Q2 2024 | -1.9% | -13.9% | +8.5% | |
| Q1 2024 | -10.7% | -4.0% | -33.2% | |
| Q4 2023 | +6.3% | +1.8% | -49.8% | |
| Q3 2023 | -7.9% | -1.3% | +11.8% | |
| Q2 2023 | +2.6% | +5.1% | +13.5% | |
| Q1 2023 | +1.4% | +5.6% | -8.5% | |
| Q4 2022 | -7.7% | -4.9% | -19.0% | |
| Q3 2022 | +8.8% | +6.3% | -40.2% | |
| Q2 2022 | -2.5% | +5.3% | +9.8% | |
| Q1 2022 | +7.9% | +10.9% | +11.3% | |
| Q4 2021 | +18.4% | +13.8% | -25.7% | |
| Q3 2021 | +5.5% | +4.9% | -66.8% | |
| Q2 2021 | -7.0% | -15.0% | -30.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro